title: Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies.
abstract: Advances in vascular radiology techniques for superselective arterial infusions and methods to overcome systemic toxicity from high-dose cisplatin chemotherapy encouraged us to reevaluate the effects of rapid regional cisplatin infusion for patients with head and neck malignancies. Twenty patients (17 carcinomas, three sarcomas) received high-dose cisplatin (100-200 mg/m2) by this method. Fifteen of the 17 patients with upper aerodigestive tract carcinoma are part of an ongoing phase I dose escalation of cisplatin with sodium thiosulfate neutralization. Three additional patients with sarcomas were treated with intra-arterial (IA) cisplatin and systemic Adriamycin. Fifty-three IA infusions were performed without any complications. Only minimal toxicity related to the chemotherapy was observed. The overall response rate for previously untreated patients was nine of 10 (90%) [complete response (CR) 67%; partial response (PR) 33%]. The response rate for patients with recurrent disease was five of eight (63%) (CR 20%, PR 80%). The average length of follow-up is 9.5 months and the actuarial survival rate is 56%. Superselective rapid infusion of high-dose cisplatin for patients with advanced head and neck malignancies is feasible, relatively nontoxic, and may have important applications in multimodality therapy, particularly for patients with bulky primary disease.
authors.affiliation: Division of Otolaryngology-Head and Neck Surgery, University of California, San Diego 92103.
authors.forename: K T
authors.initials: KT
authors.lastname: Robbins
authors.forename: A M
authors.initials: AM
authors.lastname: Storniolo
authors.forename: C
authors.initials: C
authors.lastname: Kerber
authors.forename: S
authors.initials: S
authors.lastname: Seagren
authors.forename: A
authors.initials: A
authors.lastname: Berson
authors.forename: S B
authors.initials: SB
authors.lastname: Howell
mesh_terms: D000931:Antidotes / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D005240:Feasibility Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000379:methods; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013885:Thiosulfates / Q000008:administration & dosage
chemical_list: D000931:Antidotes; D013885:Thiosulfates; D004317:Doxorubicin; C017717:sodium thiosulfate; D002945:Cisplatin